MicroRNA-223 is Associated with Resistance Towards Platinum-based Chemotherapy and Worse Prognosis in Indonesian Triple-negative Breast Cancer Patients

Figures & data

Figure 1 Immunohistochemistry of (A) CK5/6 (red arrow: positively stained in cytoplasmic membrane and cytoplasm of tumor cell). (B) EGFR (red arrow: positively stained in cytoplasmic membrane and cytoplasm of tumor cell). (C) p53 mutant (red arrow: positively stained in nucleus of tumor cell). Bar: 10 µm. Magnification: 400 times.

Table 1 AUC Value of miR-223 ROC

Area	Standard Error	p-value	95%CI
			Lower Bound	Upper Bound
0.706	0.072	0.010	0.565	0.8484

Table 2 Clinicopathologic Profile of TNBC Patients with miR-223 Underexpression and Overexpression

Parameter	miR-223 Underexpressed	miR-223 Overexpressed	p-value
	(n=20)	(n=33)
EGFR
Positive	7	23	0.013^a
Negative	13	10
CK5/6
Positive	10	20
Negative	10	13	0.57
p53 Mutant
Positive	7	15
Negative	13	18	0.454
Stage
Early	3	4
Locally- advanced	16	22
Metastatic	1	7	0.209
Tumor size
<5 cm	4	9
≥5 cm	16	24	0.555
Nodal status
Positive	12	24
Negative	8	9	0.336
Distant metastasis
Present	1	7
Absent	19	26	0.113
Age
<50 y.o	6	17
≥50 y.o	14	16	0.126
BMI
<25	11	23
≥25	9	10	0.279
Chemotherapy regimen
Platinum	9	14
Non-platinum	11	17
Missing	0	2	0.559

Note:^aStatistically significant.

Abbreviations: CK5/6, cytokeratin 5/6; BMI, body mass index.

Figure 2 ROC Curve of miR-223 to Predict 36-months OS with AUC of 0.706.

Table 3 Mean OS of TNBC Patients According to miR-223 Expression

miR-223 Expression	Mean OS (Month)	Standard Error (Month)	95%CI
			Lower Bound (Month)	Upper Bound (Month)
Underexpressed	30.225	1.997	26.311	34.139
Overexpressed	25.655	1.578	22.561	28.748
Overall	27.379	1.275	24.880	29.879

Abbreviation: OS, overall survival.

Figure 3 Kaplan–Meier Overall Survival Curve of All TNBC Patients According to miR-223 Expression.

Figure 4 Kaplan–Meier Overall Survival Curve of TNBC Patients Treated with Platinum-containing Regimen According to miR-223 Expression.

Figure 5 Kaplan–Meier Overall Survival Curve of TNBC Patients Treated with Non-platinum-containing Regimen According to miR-223 Expression.